Obsessive-compulsive disorder psychedelic and ketamine research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
26 registered studies are counted for obsessive-compulsive disorder (OCD). By compound: 10 psilocybin, 1 MDMA and 15 ketamine. By registry status: 7 recruiting, 1 not yet recruiting, 2 enrolling by invitation, 2 active, not recruiting, 11 completed and 3 terminated. By phase: 1 early phase 1, 10 phase 1, 10 phase 2, 1 not applicable and 4 not reported. Reported start years run from 2009 (earliest) to 2026 (latest).
Studies are matched when the title names obsessive-compulsive disorder or OCD alongside a psychiatric or compound term. Osteochondritis dissecans is not matched. Studies are matched by keyword on the title as registered, so a study can be missed and a study that mentions the condition only in passing can be included. A study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 26 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 10 |
| MDMA | 1 |
| Ketamine | 15 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 7 | 27% |
| Not yet recruiting | 1 | 4% |
| Enrolling by invitation | 2 | 8% |
| Active, not recruiting | 2 | 8% |
| Completed | 11 | 42% |
| Terminated | 3 | 12% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 1 | 4% |
| Phase 1 | 10 | 38% |
| Phase 2 | 10 | 38% |
| Not applicable | 1 | 4% |
| Not reported | 4 | 15% |
Countries
Country is taken from the study's linked research site. 0 of 26 records have no country on file. The top 6 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 20 | 77% |
| Canada | 2 | 8% |
| Austria | 1 | 4% |
| United Kingdom | 1 | 4% |
| Israel | 1 | 4% |
| Poland | 1 | 4% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 8 |
| 2020 to 2023 | 6 |
| 2015 to 2019 | 5 |
| 2010 to 2014 | 5 |
| Before 2010 | 2 |
Study design
- 22 interventional and 4 observational studies.
- Median planned or actual enrolment is 25 participants (range 1 to 1,000, across 26 records that report it).
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Psilocybin for Treatment of OCD-2 | NCT06992999 | Not yet recruiting | Phase 1 | 2026-01-01 | Psilocybin |
| Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder. | NCT07347405 | Recruiting | Phase 1 | 2026-01-01 | Psilocybin |
| MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study) | NCT05783817 | Recruiting | Phase 2 | 2025-09-10 | MDMA |
| Assess the Utility of a Speech-based Machine Learning Algorithm to Predict Treatment Response to Psychiatric Interventions | NCT06823024 | Enrolling by invitation | Not reported | 2025-02-18 | Ketamine |
| Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe OCD | NCT04882839 | Recruiting | Phase 2 | 2024-11-25 | Psilocybin |
| Open-Label Psilocybin Study in Transdiagnostic Population | NCT06442423 | Recruiting | Phase 1 | 2024-10-17 | Psilocybin |
| Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD | NCT06299319 | Completed | Phase 1 | 2024-09-01 | Psilocybin |
| Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2) | NCT05940324 | Recruiting | Phase 2 | 2024-02-24 | Ketamine |
| Effects of Repeated Psilocybin Dosing in OCD | NCT05370911 | Active, not recruiting | Phase 1 | 2023-07-20 | Psilocybin |
| Effects of Psilocybin in Obsessive Compulsive Disorder | NCT05546658 | Active, not recruiting | Early Phase 1 | 2022-11-28 | Psilocybin |
| PsilOCD: A Pharmacological-Challenge Feasibility Study | NCT06258031 | Completed | Phase 1 | 2022-10-28 | Psilocybin |
| Ketamine in OCD: Efficacy and Effects on Stress and Cognition | NCT05577585 | Recruiting | Not applicable | 2022-10-01 | Ketamine |
| Ketamine Safety and Tolerability in Psychiatric Inpatient Care (KetGD) | NCT05565352 | Enrolling by invitation | Not reported | 2022-09-01 | Ketamine |
| University of Iowa Interventional Psychiatry Service Patient Registry | NCT04480918 | Recruiting | Not reported | 2020-11-02 | Ketamine |
| Chart Review of Patients Undergoing Ketamine Infusions | NCT04209296 | Completed | Not reported | 2019-12-03 | Ketamine |
| Psilocybin for Treatment of Obsessive Compulsive Disorder | NCT03300947 | Completed | Phase 1 | 2019-01-02 | Psilocybin |
| Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study. | NCT03356483 | Completed | Phase 1 | 2018-11-13 | Psilocybin |
| Understanding How Ketamine Brings About Rapid Improvement in OCD | NCT02624596 | Completed | Phase 2 | 2016-06-01 | Ketamine |
| Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD) | NCT02422290 | Completed | Phase 1 | 2015-03-01 | Ketamine |
| Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCD | NCT02206776 | Terminated | Phase 2 | 2014-09-01 | Ketamine |
| A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder | NCT02234011 | Terminated | Phase 2 | 2014-09-01 | Ketamine |
| Extending Ketamine's Effects in OCD With Exposure and Response Prevention (EX/RP) | NCT02062658 | Completed | Phase 2 | 2013-12-01 | Ketamine |
| Intravenous Ketamine in the Treatment of Obsessive-Compulsive Disorder | NCT01371110 | Terminated | Phase 1 | 2012-06-01 | Ketamine |
| Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD) | NCT01100255 | Completed | Phase 2 | 2010-04-01 | Ketamine |
| Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive Disorder | NCT00956085 | Completed | Phase 2 | 2009-08-01 | Ketamine |
| Ketamine Infusion for Obsessive-Compulsive Disorder | NCT01349231 | Completed | Phase 2 | 2009-02-01 | Ketamine |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | MDMA | Ketamine
Other condition hubs
Depression | Treatment-resistant depression | Bipolar disorder | Post-traumatic stress disorder | Alcohol use disorder | Opioid use disorder | Tobacco and nicotine use | Cocaine and methamphetamine use | Anxiety | Cancer and end-of-life distress | Eating disorders | Headache and migraine | Chronic pain | Suicidal ideation and suicide risk